ArticleTranslational cancer research2026

The place of acalabrutinib-obinutuzumab combination in the first-line treatment of patients with chronic lymphocytic leukemia.

Agnieszka Szymczyk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.